|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:alsoKnownAs
|
gptkb:Ivacaftor
|
|
gptkbp:approvalYear
|
2012
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:R07AX02
|
|
gptkbp:bioavailability
|
high
|
|
gptkbp:CASNumber
|
873054-44-5
|
|
gptkbp:chemicalClass
|
quinoline derivative
|
|
gptkbp:contraindication
|
hypersensitivity to ivacaftor
|
|
gptkbp:developedBy
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:hasMolecularFormula
|
C24H28N2O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
VX-770
|
|
gptkbp:indication
|
gptkb:cystic_fibrosis_with_G551D_mutation
|
|
gptkbp:interactsWith
|
CYP3A inducers
CYP3A inhibitors
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Kalydeco
|
|
gptkbp:mechanismOfAction
|
CFTR potentiator
|
|
gptkbp:metabolism
|
liver (CYP3A4, CYP3A5)
|
|
gptkbp:molecularWeight
|
392.49 g/mol
|
|
gptkbp:patent
|
gptkb:Vertex_Pharmaceuticals
|
|
gptkbp:pregnancyCategory
|
B (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2108508
16220172
DB08820
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
diarrhea
abdominal pain
dizziness
headache
rash
upper respiratory tract infection
|
|
gptkbp:target
|
gptkb:CFTR_protein
|
|
gptkbp:UNII
|
6S6W9VH7F8
|
|
gptkbp:usedFor
|
treatment of cystic fibrosis
|
|
gptkbp:bfsParent
|
gptkb:Kalydeco
|
|
gptkbp:bfsLayer
|
6
|